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cBackground: Methicillin-resistant Staphylococcus aureus (MRSA) com-
plicated skin and skin structure infection (cSSSI) is a prominent infec-
tion encountered in hospital and outpatient settings that is associated
with high resource use for the health-care system. Objective: A deci-
sion analytic (DA) model was developed to evaluate the cost-effective-
ness analysis (CEA) of linezolid, daptomycin, and vancomycin in MRSA
cSSSI. Methods: Bayesian methods for evidence synthesis were used
to generate efficacy and safety parameters for a DA model using pub-
lished clinical trials. CEA was done from the US health-care perspec-
tive. Efficacy was defined as a successfully treated patient at the test of
cure without any adverse reaction. Primary outcome was the incre-
mental cost-effectiveness ratio between linezolid and vancomycin,
daptomycin and vancomycin, and linezolid and daptomycin in MRSA
cSSSI. Univariate and probabilistic sensitivity analyseswere performedlinezolid, daptomycin, and vancomycin were $18,057, $20,698, and O
o rep
mics
e Dri
al So
doi:10.1016/j.jval.2010.12.00623,671, respectively. The cost-effectiveness ratios for linezolid, daptomy-
in, and vancomycin were $37,604, $44,086, and $52,663 per successfully
reated patient, respectively. Linezolid and daptomycin were dominant
trategies compared to vancomycin. However, linezolid was dominant
hen compared to daptomycin. Themodel was sensitive to the duration
f daptomycin and linezolid treatment. Conclusion: Linezolid and dap-
omycin are potentially cost-effective based on the assumptions of the
A model; however, linezolid appears to be more cost-effective com-
ared to daptomycin and vancomycin for MRSA cSSSIs.
eywords: Bayesian methods, complicated skin and skin structure
nfections, cost-effectiveness analysis, daptomycin, decision analysis
odel, linezolid, methicillin-resistant Staphylococcus aureus, vancomy-
in.to test the robustness of the model. Results: The total direct costs of Copyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Complicated skin and skin structure infections (cSSSIs) are com-
monly encountered in both the community as well as the nosoco-
mial settings and encompass a wide spectrum of infections from
superficial impetigo andmild cellulitis to severe infections involv-
ing deeper fascia (e.g., abscess and surgical site infections) [1].
cSSSIs are primarily caused by gram-positive bacteria, including
Staphylococcus aureus and -hemolytic streptococci [1,2]. Methicil-
lin-resistant S. aureus (MRSA) has become the predominant patho-
gen in cSSSIs [3,4]. The impact of cSSSIs caused by MRSA has been
associated with increased length of hospital stay and resource use
compared to infections caused bymethicillin-sensitive strains [5].
Although vancomycin is still considered by many to be the gold
standard in the management of MRSA cSSSIs, several studies have
demonstrated the superiority of alternative agents such as linezolid
and daptomycin [6–8]. More specifically, Weigelt et al. [6] reported
better overall outcomes for linezolid compared tovancomycin (88.6%
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1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.vs. 66.9%, P 0.001) for a subgroup of patients with cSSSI caused by
MRSA. Furthermore, in ameta-analysis of linezolid and vancomycin
for themanagement ofMRSA cSSSIs, a higher rate ofmicrobiological
eradication was observed for patients managed with linezolid than
with vancomycin (odds ratio 2.90; 95% confidence interval 1.90–4.41)
[7]. Similarly, Davis et al. [8] described a more rapid resolution of
symptoms and clinical cure for patients managed with daptomycin
compared to a vancomycin historical control. It should also be noted
that, in this study, a shorter median antibiotic-related length of stay
(LOS) was observed with the daptomycin arm compared to the van-
comycin arm (4 days vs. 8 days, P 0.01).
We previously evaluated the cost-effectiveness of linezolid
versus vancomycin for the management of MRSA cSSSIs [9]. Al-
though inpatient intravenous (IV) vancomycin therapy with tran-
sition to outpatient IV therapy was determined to be the most
cost-effective strategy, for payerswith a higherwillingness-to-pay
threshold (WTP), IV linezolid therapywith transition to outpatient
oral therapy would be more cost-effective given its associated
ort.
Clinical Specialist, Pharmacoeconomics/Formulary Management,
ve (119), San Diego, CA 92161, USA.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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632 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 3 1 – 6 3 9greater efficacy [9]. Similarly, in a cost-effectiveness analysis of
daptomycin versus vancomycin for MRSA cSSSIs using a decision
analysis (DA) model, we reported potential cost savings with dap-
tomycin [10]. Currently, no study exists that comparatively evalu-
ates the effectiveness of linezolid and daptomycin for the man-
agement of MRSA cSSSIs. Available studies have compared these
novel agents either to vancomycin or beta-lactams (e.g., oxacillin/
nafacillin).
Indirect treatment comparison using Bayesian hierarchicalmod-
els provides a uniquemethod to compare treatments in the absence
of head-to-head trials [11–14]. Bayesian hierarchical models using
Markov chain Monte Carlo (MCMC) simulations can be applied to
provide indirect comparison of linezolid and daptomycin through a
common comparator (e.g., vancomycin) [11–14]. An advantage of us-
ing the Bayesian random-effects indirect treatment comparison
model is the production of absolute probabilities for each treatment
that can then be incorporated into a DA model. Although no direct
comparisonexists, Bayesianmethods for evidence synthesis provide
auseful tool to generateparameters for aDAmodel [12]. Thiswas the
first study to apply Bayesian methods for evidence synthesis in a
cost-effectiveness analysis comparing vancomycin, linezolid, and
daptomycin for MRSA cSSSIs in a DAmodel.
Methods
DA Model
ADAmodelwas built to evaluate the cost-effectiveness analysis of
vancomycin, linezolid, and daptomycin in MRSA cSSSIs. The
model possessed three main branches, one for each of the treat-
ment strategies. Each arm of the model represented a clinical
Table 1 – Description of the pathways used in the model.
Strategy
MRSA ()/success/no ADR Patients were s
cultures were
were positive
complete the
MRSA ()/success/ADR/switched to tigecycline Patients were s
cultures on d
experienced
mg IV for 14 d
MRSA ()/failure/switched to tigecycline Patients were s
cultures on d
determined t
days with an
MRSA ()/switched to oxacillin  dicloxacillin Patients were s
negative on d
discharged w
ADR, adverse reaction; IV, intravenously; MRSA, methicillin-resistan
Fig. 1 – Decision analysis model. The squares represent the de
strategies is made (linezolid, daptomycin, and vancomycin). C
the pathway that a trial simulation will travel. Triangles repre
of the pathway are collected. cSSSI, complicated skin and skin st
Staphylococcus aureus; MRSA (−), negative culture for methicillin-respathway that a patient can experience, which is described in Table
1. A schematic diagram of the decision analysis model is illus-
trated in Figure 1. Treatment doses were based on the clinical
literature: vancomycin 1000 mg every 12 hours, linezolid 600 mg
every 12 hours, and daptomycin 4 mg/kg/day for an 80-kg patient
[1]. Patients with a diagnosis of cSSSI were treated empirically for
MRSA cSSSIs. Culture for MRSA was performed on the day of sus-
pected cSSSI (day 0) and confirmed at day 2. It was assumed that
MRSA was present in 59% of patients with cSSSIs [15]. Oxacillin and
dicloxacillin were used for patients who had a negative culture of
MRSA.
Success was defined as clinical resolution of signs and symptom
ofMRSAcSSSI infection at the test of cure. Thiswas interpreted from
theclinical trials as all patientswhowere clinically assessable,which
was defined as all patients in the intention-to-treat population who
received the study drug, adhered to the protocol, and had sufficient
data available to make inferences about the study drug with clinical
outcome. Discontinuation due to an adverse reaction (ADR) to the
study drug was also modeled in the simulation. Vancomycin infu-
sion was assumed to be 60 minutes for every gram, and the total
length of linezolid therapy (IV followed by oral formulation) was 15
days [16].
Meta-analysis
Literature search
Building on the previous work of two meta-analyses [9,17], we
performed a literature search to identify other studies that may
not have been included. A PubMed search was performed from
inception to May 2010 using the following combination of key
words: linezolid, daptomycin, vancomycin, skin and soft tissue
Description
on intravenous (IV) antibiotic empirically on day 1. Microbiological
ormed on day 1, and results were available on day 2. MRSA cultures
patients would continue on IV antibiotic treatment. Patients would
ntibiotic course and not experience a relapse at the test of cure
on IV antibiotic empirically on day 1, and had positive MRSA
Patients were continued on their IV antibiotic course but
and had to be switched. Patients were switched to tigecycline 50
ith an initial dose of 100 mg and assumed to respond
on IV antibiotic empirically on day 1 and had positive MRSA
Patients were continued on their IV antibiotic course but were
onresponders on day 5 and switched to tigecycline 50 mg IV for 14
l dose of 100 mg and assumed to respond
on IV antibiotic empirically on day 1, but MRSA cultures were
Patients were then switched to IV oxacillin for 5 days and
days of dicloxacillin
hylococcus aureus.
n mode where the decision to use one of the three treatment
represent the chance node where probabilities determine
the terminal nodes where the total direct costs and benefits
re infection; MRSA (+), positive culture for methicillin-resistanttarted
perf
, and
ir IV a
tarted
ay 2.
ADRs
ays w
tarted
ay 2.
o be n
initia
tarted
ay 2.
ith 10cisio
ircles
sent
ructuistant Staphylococcus aureus; ADR, adverse reaction.
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633V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 3 1 – 6 3 9infection, skin and skin structure infection, and methicillin-
resistant Staphylococcus aureus. Studies that were prospective
trials, with two or more of the study drugs, using an adult sam-
ple (age 18 years and older), and had clinical efficacy as an out-
come measure were included.
Clinical outcomes
Bayesian indirect treatment comparison was used to determine
the probabilities of success for the study therapies (e.g., linezolid,
daptomycin, and vancomycin), which were incorporated into the
DA model. A central assumption of indirect or mixed treatment
comparison analysis is that the direct estimate of a treatment
effect between C and B, dBC, is equivalent to the difference in
reatment effects between B, C, and A, their common comparator:
BC dAC dAB [14]. In assessing dBC, strength is borrowed from
tudies in which dAC or dAB is assessed. When multiple interven-
ions are linked by a connected network of evidence, indirect or
ixed treatment comparison allows for treatments to be rank-
rdered in terms of their effectiveness on an absolute (e.g., prob-
bility) scale for all connected interventions. Joint posterior distri-
utions of the absolute treatment effect of each study therapy
ere estimated with MCMC using theWinBUGS software package
WinBUGS v1.4; Imperial College andMRC, London, UK) [18]. Vague
riors were used to reduce the influence of previous distribution
n the observed results and provide information similar to that
sing a conventional frequentist approach [19]. To reflect potential
eterogeneity between studies, a normally distributed random-
ffectsmodel on the log-odds scale was used tomodel the relative
reatment effects [20]. A uniform distribution was selected for the
etween-study variance, which provided the least influence on
he posterior distribution [21]. Convergence was visually assessed
fter a burn-in of 5000 iterations; 10,000 subsequent iterations
ere used for inference [22]. Discontinuation due to ADR to the
tudy therapies was estimated using a similar approach. Draws
rom the MCMC were exported using the Convergence Diagnos-
ic and Output Analysis (CODA v0.30; MRC Biostatistics Unit,
ambridge, UK) function and then incorporated into the DA
odel to maintain correlation in the joint posterior distribu-
ion. WinBUGS code is presented in Appendix A at doi:10.1016/
.jval.2010.12.006.
Table 2 – Cost of items in the decision analysis model.
Item Cost ($US) 25%
Drug cost per day
IV vancomycin (1 g BID) 14.00 3.5
IV linezolid (600 mg BID) 240.22 60.0
PO linezolid oral (600 mg BID) 183.95 45.9
IV daptomycin (80-kg patient) 272.70 68.1
IV oxacillin (2 g every 6 hr) 103.08 25.7
PO dicloxacillin (500 mg every 6 hr) 4.80 1.2
Tigecycline treatment cost 1102.50 275.6
Hospitalization (1 day) 2132.51 533.1
Vancomycin trough 6.70 1.6
Microbiological culture 43.78 10.9
Platelet monitoring 9.16 2.2
SCr monitoring 2.03 0.5
BID, twice daily; IV, intravenous; LL, lower limit; PO, oral; SCr, serum
* A 25% variance of the point estimate was used in the probabilistic
† Lower limit and upper limit were used in the univariate analysis.
‡ Health Economic Resource Center, 2006 report. All costs were adju
§ Decision Support Services, 2008 report. All costs were adjusted for 2009Economic analysis
This analysis was conducted from the perspective of the US
health-care payer; therefore, US dollars were used. All costs were
adjusted for 2009 based on the medical component of the Con-
sumer Price Index (Table 2). Total direct costs included acquisition
costs of the study medications, laboratory analysis, microbiology,
and a night of hospital stay. Acquisition costs of the study thera-
pies were determined from the Drug Red Book [23]. Costs of daily
hospital stay, vancomycin levels (trough), platelet monitoring, re-
nal panels, and microbiological cultures were based on the Deci-
sion Support System (DSS) database. DSS is the Veterans Affairs
(VA) national database that provides resource utilization directed
at patient care. Information was pulled from VA hospitals across
the country and itemized for easy interpretation of resource utili-
zations. Cost parameters and resource utilization were modeled
using gamma and triangular distributions, respectively [24].
The primary outcome of interest was the incremental cost per one
dditional treatment success, otherwise known as the incremental
ost-effectiveness ratio (ICER). ICERs were calculated using the follow-
ng equation: (CTreatment A  CTreatment B)/(ETreatment A  ETreatment B),
where C is the total direct costs of the treatment, E is the effect or
enefit of the treatment, Treatment A is the study drug of interest,
nd Treatment B is the comparator [24,25]. Average cost-effective-
ess ratios were calculated as total direct costs divided by the
fficacy (C/E) for each of the study comparisons [24,25]. Cost-effec-
iveness was evaluated for the following pairwise comparisons:
inezolid versus vancomycin, daptomycin versus vancomycin,
nd linezolid versus daptomycin because these were the most
elevant comparisons to decision makers. A dominant strategy is
ne inwhich the incremental cost of the study drug is less than the
omparator and the incremental efficacy is greater than the com-
arator [24,25]. Discounting was not applied because of the short
ime frame of the study.
Assumptions
Patients who had a culture negative for MRSA on day 2 were
switched to an oxacillin/dicloxacillin regimen and presumed to
respond to the alternative therapy. Gram-negative coverage was
assumed to be similar between treatment arms and not included
in the analysis. Patients receiving vancomycin would have an ini-
tial serum creatinine laboratory value obtained as well as a fol-
LL ($US)† UL ($US) Distribution Ref.
10.50 17.50 Gamma [21]
180.17 300.28 Gamma [21]
137.96 229.94 Gamma [21]
204.53 340.88 Gamma [21]
77.31 128.85 Gamma [21]
3.60 6.01 Gamma [21]
826.88 1378.13 Gamma [21]
1599.38 2665.64 Gamma HERC‡
5.03 8.38 Gamma DSS§
32.84 54.73 Gamma DSS
6.87 11.45 Gamma DSS
1.52 2.54 Gamma DSS
tinine; UL, upper limit.
tivity analysis.
for 2009 US Dollars ($US).*
0
6
9
8
7
0
3
3
8
5
9
1
crea
sensi
stedUS dollars ($US).
634 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 3 1 – 6 3 9low-up onday 3. In addition, a vancomycin troughwould be drawn
every 3 days to simulate blood serummonitoring. Linezolid would
be monitored for thrombocytopenia at least once while on ther-
apy. Patients in whom therapy was considered a failure were
switched to tigecycline 50mg IV for 14 days (with an initial dose of
100 mg on day 1) and assumed to be complete responders [26]. All
clinical outcomes were assumed to be reported at the test of cure.
Death was not included in our model as a possible clinical path-
way because we assumed that the contribution to the outcome of
cSSSIs was minimal.
Patients receiving linezolid for empirical therapy were as-
sumed to receive 5.4 days of IV therapy and then discharged on 9.6
days of oral linezolid for a total of 15 days of treatment (Table 3)
[16]. Patients started on daptomycin empirically were assumed
to receive their entire course of therapy in the hospital (6.1 days)
until resolution of signs and symptoms [27]. Patients started on
vancomycin empirically were assumed to receive their entire
course of therapy (14 days) in the hospital until resolution of
signs and symptoms [16,28]. In addition, patients had the van-
comycin trough monitored every 3 days.
Sensitivity analyses
In the indirect treatment comparison evaluating discontinuation
due to an ADR, the point estimates used in the DA model were
small.Wewanted to investigate the upper limit of the 95% credible
interval (CrI), the Bayesian analogue to the standard confidence
interval, and performed a sensitivity analysis using the higher val-
Table 3 – Resource utilization.
Point estimate
Antibiotic-related LOS, days
Vancomycin 14
Linezolid 5.4
Daptomycin 6.1
Oxacillin 5
Duration of PO linezolid, days 9.6
Duration of PO dicloxacillin, days 10
No. of days until clinical response 5
LL, lower limit; LOS, length of stay; PO, oral; UL, upper limit.
* Lower limit and upper limit were used in the univariate analysis.
Table 4 – Characteristics of the studies.
Study Drugs Age in years of
experimental
Age in ye
compar
Davis et al.,
2007 [8]
Daptomycin vs. vancomycin Median 45
(range 19–67)
Median 45
(range 1
Arbeit et al.,
2004 [34]
Daptomycin vs. comparators* Mean 51.5
(range 18–91)
Mean 51.9
(range 1
Katz et al.,
2008 [35]
Daptomycin vs. vancomycin Mean 43.5
(range 18–77)
Mean 41.0
(range 1
Pertel et al.,
2009 [36]
Daptomycin vs. vancomycin Median 54
(range 125–79)
Median 48
(range 1
Stevens et al.,
2002 [37]
Linezolid vs. vancomycin Mean 63.9
(SD 16.1)
Mean 59.8
(SD 20.2
Weigelt et al.,
2004 [38]
Linezolid vs. vancomycin Mean 60
(SD 16)
Mean 60
(SD 18)
Weigelt et al.,
2005 [6]
Linezolid vs. vancomycin Mean 52
(SD 18)
Mean 52
(SD 18)
Kohno et al.,
2007 [39]
Linezolid vs. vancomycin Mean 68.4
(SD 16.4)
Mean 67.5
(SD 16.3
Wilcox et al.,
2009 [40]
Linezolid vs. vancomycin Mean 53.7
(SD 18.1)
Mean 53.8
(SD 17.6
CE, clinical evaluation; MRSA, methicillin-resistant Staphylococcus au
* Comparators include penicillinase-resistant penicillin or vancomycin.ues as the point estimates (scenario 1). In scenario 2, we investi-
gated the change in ICER when the LOS of patients treated with
vancomycinwas reduced from 14 to 8 days [8,29]. In scenario 3, we
investigated the change in ICER when the duration of IV linezolid
was reduced from 5.4 to 1.8 days to take advantage of linezolid’s
100% bioavailability [29]. In scenario 4, we investigated the change
in ICER when the duration of IV daptomycin was reduced from 6.1
to 4 days based on the results from one study [8].
Univariate (one-way) sensitivity analysis was performed for all
parameters in the base-case DA model for the comparison of lin-
ezolid and daptomycin. Mean probabilities generated from the
Bayesian random-effects meta-analysis was used along with the
calculated 95% CrI. Probabilistic sensitivity analysis (second-order
Monte Carlo simulation) was performed for all comparisons using
10,000 trial simulations and plotted on a cost-effectiveness plane
[30,31]. Uncertainties of the cost-effectiveness for the treatment of
interest versus the comparator based on the cumulative density
functionwith increasingWTPwerepresentedasacceptability curves
[31–33]. Analyses were performed using TreeAge Pro Suite 2009 (re-
lease 1.5.1; TreeAge Software, Inc., Williamstown, MA, USA).
Results
A total of 9 studies were used to generate efficacy and discontin-
uation due to ADR probabilities based on the Bayesian method of
indirect treatment comparison [6,8,34–40]. Characteristics of each
LL* UL Distribution Refs.
3 19 Triangular [8, 27]
1 10 Triangular [26, 27]
4 14 Triangular [8, 33, 44, 46]
3 7 Triangular [35]
4 15 Triangular [26, 27]
5 15 Triangular [35]
2 7 Triangular [44, 45]
CE results of
experimental
CE results of
comparator
MRSA of
experimental
MRSA of
comparator
41/53 (77.4%) 89/212 (42.0%) NR NR
372/446 (83.6%) 384/456 (84.2%) 21/28 (75.0%) 25/36 (69.4%)
32/39 (82.1%) 37/39 (94.9%) 22/31 (71.0%) 24/28 (85.7%)
)
22/28 (78.6%) 16/22 (72.7%) NR NR
9/17 (52.9%) 5/10 (50.0%) 13/18 (72.2%) 4/10 (40.0%)
53/57 (93.0%) 48/55 (87.3%) 41/49 (83.7%) 28/49 (57.1%)
39/45 (86.7%) 31/39 (79.5%) 42/48 (87.5%) 34/39 (87.2%)
64/99 (64.6%) 54/87 (62.1%) 27/34 (79.4%) 22/30 (73.3%)
439/476 (92.2%) 402/454 (88.5%) 124/140 (88.6%) 97/145 (66.9%)ars of
ator
9–73)
7–94)
8–86)
18–86
)
)
)
reus.
635V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 3 1 – 6 3 9study and data used in themeta-analyses are presented in Table 4.
Four studies were used for daptomycin [8,34–36], and five studies
were used for linezolid [6,37–40]. All studies used vancomycin as
the comparator except for one study, which used beta-lactams
and vancomycin [34]. The mean age of the experimental drug
ranged from 43.5 years to 68.4 years, and the mean age of the
comparator ranged from 41.0 years to 67.5 years.
In the Bayesianmeta-analysis, linezolid had a higher probabil-
ity of success at the test of cure (82%) followed by daptomycin
(80.1%) and vancomycin (76.7%). However, daptomycin had a
lower probability of patients discontinuing empirical therapy due
to an ADR (0.1%) compared to linezolid (0.2%) and vancomycin
(0.2%). Mean probabilities with SDs and 95% CrIs are presented in
Table 5.
In the base-case analysis, linezolid and daptomycin were
dominant compared to vancomycin (Table 6). However, when
compared to daptomycin, linezolid was a dominant strategy.
The total direct costs for linezolid, daptomycin, and vancomy-
cin were $18,057, $20,698, and $23,671, respectively. The cost-
effectiveness ratios for linezolid, daptomycin, and vancomycin
were $37,604, $44,086, and $52,663 per successfully treated pa-
tient, respectively. Extended dominance was not observed in
the cost-effectiveness frontier (not shown).
In the one-way sensitivity analyses comparing linezolid to
daptomycin, the base-case ICER was sensitive to three model pa-
rameters (Table 7). If the duration of IV daptomycin was de-
creased, linezolid was no longer a dominant strategy. If the du-
rations of linezolid oral and IV therapy were increased, linezolid
was no longer a dominant strategy. For all other parameters, the
model was robust. The model was also robust in most of the
different scenarios investigated (scenarios 1, 2, and 3) with the
exception of scenario 4, in which the duration of IV daptomycin
was changed from 6.8 to 4 days (Table 8). In scenario 4, linezolid
was no longer a dominant strategy.
Table 5 – Base-case parameters of the decision analysis m
Variable Mean SD
Success*
Vancomycin 0.767 0.0
Linezolid 0.820 0.0
Daptomycin 0.801 0.0
Heterogeneity parameter () 0.777 0.3
Discontinuation due to ADR*
Vancomycin 0.002 0.0
Linezolid 0.002 0.0
Daptomycin 0.001 0.0
Heterogeneity parameter () 0.381 0.3
Mean SD
Probability of MRSA () 0.590 0.1
ADR, adverse reaction; CrI, credible interval; LL, lower limit; MRSA, m
* Bayesian meta-analysis was performed to generate the probabilitie
† Lower limit and upper limit were used in the univariate analysis.
Table 6 – Base-case results of probabilistic sensitivity anal
Strategy Total costs SD Incremental
costs
Efficacy
Vancomycin $23,671 $7069 0.449 0
Linezolid $18,057 $4840 $5614 0.480 0
Daptomycin $20,698 $5632 $2973 0.469 0CER, cost-effectiveness ratio; DAP, daptomycin; ICER, incremental cost-efResults of the probabilistic sensitivity analysis were plotted on
an incremental cost-effectiveness plane comparing linezolid and
vancomycin, daptomycin and vancomycin, and linezolid and dap-
tomycin (Fig. 2). For all comparisons, a majority of the ICER scat-
terplots were in the dominant quadrant (less costly and more ef-
fective). In the probabilistic sensitivity analysis comparing
linezolid and vancomycin, 75.34% of the ICER scatterplots were in
the dominant quadrant. In the comparison of daptomycin and
vancomycin, 57.38% of the ICER scatterplots were in the dominant
quadrant. In the comparison of linezolid and daptomycin, 48.08%
of the ICER scatterplots were in the dominant quadrant.
Acceptability curves were created for all comparisons: lin-
ezolid and vancomycin, daptomycin and vancomycin, and lin-
ezolid and daptomycin (Fig. 3). Linezolid was a cost-effective
strategy across the WTP range investigated compared to vanco-
mycin and daptomycin; and daptomycin was a cost-effective
strategy across the WTP range investigated compared to vanco-
mycin. The acceptability curve dropped slightly in the linezolid
and daptomycin comparison; however, the curve plateaued and
remained greater than 50%, favoring linezolid.
Discussion
Clinical outcomes associated with the management of cSSSIs are
influenced by multiple factors such as host comorbidities, size of
infected lesion, surgical intervention, selectionof antibiotics, and the
infecting organism(s) [41]. More specifically, MRSA cSSSIs are associ-
atedwithpoorer treatment outcomes compared to infections caused
by methicillin-sensitive strains, with an increased risk of concomi-
tant bacteremia, need for amputation, and mortality [42–44]. Al-
though vancomycin remains the gold standard for themanagement
of MRSA cSSSIs, intolerance and adverse effects associated with ad-
ministration and/or use of the antibiotic often limits its usefulness.
.
2.5% (CrI) 97.5% (CrI) Refs.
0.721 0.811 [7, 17]
0.681 0.921 [7]
0.609 0.917 [17]
0.286 1.618
3.52E-13 0.015 [7, 17]
3.93E-13 0.017 [7]
2.35E-13 0.011 [17]
0.023 1.303
LL† UL
0.150 0.740 [15]
cillin-resistant Staphylococcus aureus; UL, upper limit.
success and discontinuation due to ADR for the different treatments.
Incremental
efficacy
CER ICER (vs. VAN) ICER (LIN vs. DAP)
$52,663
0.031 $37,604 Dominant Dominant
0.020 $44,086 Dominantodel
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636 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 3 1 – 6 3 9Furthermore, increasing reports of MRSA demonstrating intermedi-
ate resistance to vancomycin have raised concerns [45]. As such, al-
ternative agents such as linezolid and daptomycin have become in-
creasingly more attractive as treatment options for MRSA cSSSIs.
Our studywas the first to use Bayesianmethods for indirect com-
parisons of daptomycin and linezolid. In our investigation, linezolid
anddaptomycinwere cost-effectivewhen compared to vancomycin,
primarily because of increased efficacy and reduced hospital LOS.
Several studies have shown that the use of linezolid or daptomycin
resulted in decreased LOS and increased efficacy compared to van-
comycin [6,16,27–29,46]. Reduction in LOS is an important compo-
ent in total direct costs for cSSSIs, and any advantage that a medi-
ation can provide to reduce this variable would result in significant
Table 7 – One-way sensitivity analysis results comparing l
Parameter ICER
Low ICER
Duration of IV daptomycin in days $856,104
Duration of IV linezolid in days $497,403
Duration of PO linezolid in days $81,552
Cost of IV daptomycin $62,844
Cost of hospitalization $59,471
Cost of IV linezolid $57,868
Cost of PO linezolid $55,593
Probability of daptomycin success $57,688
Probability of MRSA () $53,533
Probability of linezolid discontinuation $51,871
No. of days until response $41,707
Probability of linezolid success $31,910
Probability of daptomycin discontinuation $36,409
Cost of tigecycline regimen $36,397
Cost of platelet monitoring $36,245
Cost of creatinine monitoring $36,149
A negative incremental cost-effectiveness ratio reflects that linezolid
cost-effectiveness ratio reflects that daptomycin is dominant compared
ICER, incremental cost-effectiveness ratio; IV, intravenous; LL, lower lim
Table 8 – Results of scenario analyses.
Scenario Total costs SD Incremental
costs
Efficacy
1
Vancomycin $25,964 $149 0.446 0
Linezolid $18,450 $1002 $7514 0.475 0
Daptomycin $18,776 $1269 $7189 0.467 0
2
Vancomycin $19,949 $331 0.452 0
Linezolid $18,232 $1021 $1717 0.483 0
Daptomycin $18,626 $1284 $1323 0.472 0
3
Vancomycin $25,776 $164 0.452 0
Linezolid $14,422 $1305 $11,354 0.483 0
Daptomycin $18,626 $1284 $7150 0.472 0
4
Vancomycin $25,776 $164 0.452 0
Linezolid $18,232 $1021 $7544 0.483 0
Daptomycin $16,241 $1513 $9535 0.472 0
Scenario 1: High end of the 95% credible interval for probability of di
length of stay was changed from 14 days to 8 days. Scenario 3: Linezo
4: Daptomycin hospital length of stay was changed from 6.8 days to
CER, cost-effectiveness ratio; ICER, incremental cost-effectiveness ratio; Vost savings. However, decision makers should not be solely con-
ernedwith total costs as an endpointwhenmaking a conclusionon
he cost-effectiveness of one agent over another in cSSSIs. The effi-
acy of the antibiotic needs to be balanced with its costs; moreover,
onsideration should be made for the potential for antimicrobial re-
istance, which was not modeled in our study.
Most of the studies reported clinical outcomes at the test of
ure rather than the end of treatment. This reportingmethod cap-
ured relapse rates that would not have been seen at the end of
reatment, thereby eliminating the need to model relapse in our
tudy. However, there were two studies evaluating daptomycin
hat did not report clinical outcomes at the test of cure. As a result,
e had to assume that the outcomes reported were similar at
olid to daptomycin.
erences Range
High ICER LL UL
$181,848 4 14
$446,127 1 10
$7686 4 15
$9403 $204.53 $340.88
$12,773 $1599.38 $2665.64
$14,371 $180.17 $300.28
$16,651 $137.96 $229.94
$26,824 0.6088 0.9168
$34,919 0.15 0.74
$35,595 3.97E-13 0.01758
$27,744 2 7
$24,565 0.6814 0.9207
$34,540 2.51E-13 0.01145
$35,846 $826.88 $1378.13
$35,998 $6.87 $11.45
$36,094 $1.52 $2.54
dominant compared to daptomycin therapy. A positive incremental
nezolid. The base-case ICER is$36,122.77 (linezolid vs. daptomycin).
SA,methicillin-resistant Staphylococcus aureus; PO, oral; UL, upper limit.
Incremental
efficacy
CER ICER (vs. VAN) ICER (LIN vs. DAP)
$58,270
0.030 $38,831 Dominant Dominant
0.021 $40,213 Dominant
$44,168
0.031 $37,777 Dominant Dominant
0.020 $39,485 Dominant
$57,068
0.031 $29,881 Dominant Dominant
0.020 $39,485 Dominant
$57,068
0.031 $37,777 Dominant $182,789
0.020 $34,427 Dominant
inuation due to adverse reactions. Scenario 2: Vancomycin hospital
ospital length of stay was changed from 5.4 day to 1.4 days. Scenario
s.inez
diff
is a
to liSD
.013
.036
.045
.013
.036
.045
.013
.036
.045
.013
.036
.045
scont
lid h
4 dayAN, vancomycin; LIN, linezolid; DAP, daptomycin.
48.08%, respectively.
637V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 3 1 – 6 3 9the test of cure. Pertel et al. [36] did not provide enough infor-
mation to determine whether the results were collected at the
test of cure or the end of treatment. Similarly, Davis et al. [8]
only reported outcomes at the end of treatment. We applied the
random-effects model in our Bayesian meta-analysis to reflect
this design heterogeneity.
The LOS for each study drug varied depending on the studies
used. In scenario 4, we reported that the model was sensitive to
the changes in daptomycin duration of IV therapy. The variability
in LOS and duration of IV treatmentmay be attributed to study site
policy and protocol. Observational studies provide real-world data
on how drug therapies are used and may be more robust in a DA
model. However, the only available observational studies that we
found were based on the Cubicin Outcomes Registry and Experi-
ence (CORE) registry for daptomycin [46–48]. In the CORE registry,
themediandurationof IVdaptomycin therapy for cSSSIswas13days
(range 2–148 days) compared to the base-case number of 6.1 days
(range 4–14 days) [48]. The base-case results were sensitive to these
data and demonstrated the importance of using observational stud-
ies in DA modeling. Future analysis should use registry data or ob-
servational studies to further improve DAmodels.
The CORE registry reported variations in the daily dose for pa-
tients with cSSSIs ranging from 2.3mg/kg to 12.0mg/kg (mean 4.5,
SD 1.0 mg/kg) [46]. Although product label dose and frequency for
daptomycin (4 mg/kg/day) were mostly used, 29.7% of patients
(29/165) received daptomycin at a dose greater than 4 mg/kg/day
and 7.3% of patients (12/165) had intervals that were greater than
24 hours. Reasons for this may be a lack of initial efficacy, per-
ceived severity of illness, body weight, and renal insufficiency. It
should be noted that daptomycin demonstrates concentration-
dependent bactericidal activity. As such, the response to dapto-
mycin may improve with increasing daily dose. However, the out-
come of this relationship has not been firmly established in the
literature. Future research will need to model the higher doses of
daptomycin in special populations (e.g., hemodialysis and obese
patients) to better elucidate the clinical outcomes of dosing out-
side the product labeling.
Several treatment options are available for MRSA cSSSIs. Tige-
cycline [49], telavancin [50,51], dalfopristin/quinopristine [52],
ceftobiprole [53], ceftaroline [54], and iclaprim [55] have evidence
to support their use in MRSA cSSSIs. Tigecycline, telavancin, and
dalfopristin/quinopristine are approved by the US Food and Drug
Administration (FDA), with telavancin being the most recent.
Ceftobiprole, ceftaroline, and iclaprim are future potential agents
that could be used inMRSA cSSSIs; however, they are not currently
approved by the FDA (at the time that this articlewaswritten). The
number of novel agents for MRSA cSSSIs will require decision
makers to evaluate the cost-effectiveness of each agent relative to
another. However, the lack of direct head-to-head trials for the
newer agents will necessitate the use of Bayesian methods in ev-
idence synthesis to generate probabilities to be applied in future
DA models.
Bayesian models provide a useful method to synthesize indi-
rect comparisons among treatments that lack head-to-head trials.
We applied thismethod to develop posterior probability estimates
for linezolid and daptomycin, whichwere then incorporated into a
DA model. This approach to decision modeling has been called
“comprehensive decision modeling” [12,56]. Comparative effec-
tiveness research requires that evaluation be made between two
treatment strategies that are considered equivalent or standard of
care. The current practices, however, for FDA approval do not nec-
essarily require these types of studies for New Drug Application.
Therefore, there is a gap in the literature where relevant direct com-
parisons are unavailable, thus, contributing to the uncertainty re-
garding the relative efficacy and safety of certain novelmedications.
Bayesian methods for meta-analysis provide a framework withFig. 2 – Probabilistic sensitivity analyses results for
comparisons of linezolid and vancomycin (A), daptomycin
and vancomycin (B), and linezolid and daptomycin (C). A
drug is considered dominant if it is less costly and more
effective than its comparator (southeast quadrant).
Scatterplots on the cost-effectiveness plane represent the
individual incremental cost-effectiveness ratios drawn from
the simulation (10,000 trial simulations). Incremental cost
was based on US dollars ($US) and was plotted on the y-
axis. Incremental efficacy was based on success of the
treatment and plotted on the x-axis. The distributions of
incremental cost-effectiveness ratios scatter in the
dominant quadrant for the comparisons of linezolid and
vancomycin (A), daptomycin and vancomycin (B), and
linezolid and daptomycin (C) were 75.34%, 57.38% andwhich to estimate the differences in the absence of data. However,
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638 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 3 1 – 6 3 9validation of this method would require a large, prospective study
comparing linezolid and daptomycin.
Conclusion
By applying Bayesian random effects, indirect treatment compar-
ison, probability estimates among linezolid, daptomycin, and van-
comycin were generated and incorporated into a DA model for
MRSA cSSSIs. When compared to vancomycin, linezolid and dap-
tomycin were dominant strategies in treating MRSA cSSSIs. How-
ever, when compared to each other, linezolid was dominant com-
pared to daptomycin. Sensitivity analyses reported that themodel
was sensitive to the duration of drug therapy but not to drug costs.
Future prospective studies comparing linezolid and daptomycin
should be performed to validate the results of our comprehensive
decision model.
Supplemental Materials
Supplemental material accompanying this article can be found in
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